pyrroles has been researched along with Epstein-Barr Virus Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gru, AA; Junkins-Hopkins, JM; Williams, E | 1 |
| Ando, S; Asai, M; Goshima, F; Ito, Y; Kawada, JI; Kimura, H; Murata, T; Sato, Y; Shimizu, N; Suzuki, M; Torii, Y; Watanabe, T | 1 |
2 other study(ies) available for pyrroles and Epstein-Barr Virus Infections
| Article | Year |
|---|---|
An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation.
Topics: Aged; Arthritis, Rheumatoid; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Lymphoma, Large-Cell, Anaplastic; Male; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles | 2019 |
Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Topics: Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Epstein-Barr Virus Infections; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Janus Kinase 3; Killer Cells, Natural; Lymphocyte Activation; Lymphoma, T-Cell; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT5 Transcription Factor; T-Lymphocytes; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |